<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04519138</url>
  </required_header>
  <id_info>
    <org_study_id>BIBB EDMX01</org_study_id>
    <nct_id>NCT04519138</nct_id>
  </id_info>
  <brief_title>Investigation to Evaluate Safety and Efficacy of the Endodrill Model X Biopsy Instrument</brief_title>
  <official_title>Safety and Efficacy of the Endodrill Model X Biopsy Instrument When Sampling Tumours in the Upper Gastrointestinal Tract</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Region Skane</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bibb Instruments AB</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Key2Compliance</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Region Skane</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an investigator led prospective open label investigation, performed at three clinics&#xD;
      in Sweden, comparing the flexible endoscopic biopsy instrument Endodrill Model X with the&#xD;
      standard sampling method endoscopic ultrasound fine needle aspiration/biopsy. Assessment of&#xD;
      safety is the primary objective and performance is the secondary objective.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The investigation will include 20 patients with lesions and suspected tumors in the stomach,&#xD;
      esophagus or duodenum (upper small intestine). The investigation will consist of one visit&#xD;
      with an endoscopic examination with sampling of an observed lesion or suspected tumor. Six&#xD;
      biopsies will be collected from each patient, three consecutive samples using the Endodrill&#xD;
      Model X instrument and three consecutive samples using the standard fine needle. The order of&#xD;
      instruments to be used will be randomly assigned. The patient will be under observation for 2&#xD;
      hours after the procedure. Telephone follow-up will be performed 1 and 7 days after the&#xD;
      examination. Visual confirmation of the biopsies size will be recorded at the examination. If&#xD;
      the samples verify a tumor or not will be evaluated at Day 14 when the pathology report is&#xD;
      concluded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 30, 2020</start_date>
  <completion_date type="Anticipated">November 2021</completion_date>
  <primary_completion_date type="Anticipated">October 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>Both the Endodrill Model X device and the standard instrument are used on the same lesion and patient to evaluate both instruments and their functions under as similar circumstances as possible.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>The order of the instruments to be used is blinded to the endoscopist until after the tumor has been visualized to avoid and minimize the influence of the choice of instrument of where the sample is taken. Closed envelopes prepared according to a randomization list stratified by site are available at each site. The envelope is opened by an assistant and not shown to the examiner until the tumor has been visualized.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients with pre-specified adverse events</measure>
    <time_frame>10 days</time_frame>
    <description>Proportion of patients with one or more of the following: 1) non-intentional perforation of the sampled organ, 2) bleeding requiring open surgical intervention or treatment at an intensive care unit, 3) non-planned hospitalization for observation AND where the patient is not fully recovered within 10 days after the endoscopic examination</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Amount of visible biopsy material over or under 5 mm at endoscopy examination</measure>
    <time_frame>Day 0 (day of biopsy)</time_frame>
    <description>Visual confirmation of the biopsies size &gt; 5 mm or not, will be recorded at the examination. Analysis will be performed at each hospitals department of pathology as all biopsy samples are routinely handled. A copy of the pathology report will recorded in the Contact Report Form (CRF) at day 14 when the study report for each patient is concluded</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Tumor Sampling</condition>
  <arm_group>
    <arm_group_label>Endodrill Model X</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Three consecutive samples will be taken using the Endodrill Model X instrument.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Endoscopic ultrasound guided fine-needle aspiration/biopsy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Three consecutive samples will be taken using the the standard method fine-needle aspiration/biopsy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endodrill Model X</intervention_name>
    <description>The investigational device Endodrill Model X is used for biopsy sampling in the upper gastrointestinal tract</description>
    <arm_group_label>Endodrill Model X</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Fine-needle aspiration/biopsy</intervention_name>
    <description>The standard method is used for biopsy sampling in the upper gastrointestinal tract</description>
    <arm_group_label>Endoscopic ultrasound guided fine-needle aspiration/biopsy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adults at least 18 years of age at the day of inclusion&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
          -  Submucosal tumor of the upper gastrointestinal tract with tumor size ≥ 10 mm, well&#xD;
             localized by the endoscopic examination&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Suspicion of vascular tumor (e.g. pulsating tumor)&#xD;
&#xD;
          -  Ongoing treatment with anticoagulants (e.g. Warfarin)&#xD;
&#xD;
          -  Ongoing treatment with immunosuppressive drugs&#xD;
&#xD;
          -  Pregnancy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fredrik Swahn, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Skane University hospital, Lund, Sweden</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Fredrik Swahn, MD, PhD</last_name>
    <phone>+46723886818</phone>
    <email>Fredrik.Swahn@med.lu.se</email>
  </overall_contact>
  <location>
    <facility>
      <name>Linköping University Hospital</name>
      <address>
        <city>Linköping</city>
        <zip>581 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Glavas, MD</last_name>
      <phone>+46101030000</phone>
      <email>Robert.glavas@regionostergotland.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Skane University Hospital</name>
      <address>
        <city>Lund</city>
        <zip>251 87</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fredrik Swahn, MD, PhD</last_name>
      <phone>+46723886818</phone>
      <email>Fredrik.Swahn@med.lu.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Örebro University Hospital</name>
      <address>
        <city>Örebro</city>
        <zip>701 85</zip>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Malin Wickbom, MD</last_name>
      <phone>+46733900654</phone>
      <email>malin.wickbom@regionorebrolan.se</email>
    </contact>
  </location>
  <location_countries>
    <country>Sweden</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 17, 2020</study_first_submitted>
  <study_first_submitted_qc>August 17, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">August 19, 2020</study_first_posted>
  <last_update_submitted>September 15, 2021</last_update_submitted>
  <last_update_submitted_qc>September 15, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Endoscope</keyword>
  <keyword>Gastrointestinal</keyword>
  <keyword>Image-Guided Biopsy</keyword>
  <keyword>Fine-Needle</keyword>
  <keyword>Medical device</keyword>
  <keyword>Methods</keyword>
  <keyword>Diagnosis</keyword>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

